GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » Price-to-Owner-Earnings

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 29, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals Price-to-Owner-Earnings?

As of today (2024-04-29), NGM Biopharmaceuticals's share price is $1.54. NGM Biopharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for NGM Biopharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


NGM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.12
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-29), NGM Biopharmaceuticals's share price is $1.54. NGM Biopharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.73. Therefore, NGM Biopharmaceuticals's PE Ratio for today is At Loss.

As of today (2024-04-29), NGM Biopharmaceuticals's share price is $1.54. NGM Biopharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.73. Therefore, NGM Biopharmaceuticals's PE Ratio without NRI for today is At Loss.


NGM Biopharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for NGM Biopharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGM Biopharmaceuticals Price-to-Owner-Earnings Chart

NGM Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

NGM Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NGM Biopharmaceuticals's Price-to-Owner-Earnings

For the Biotechnology subindustry, NGM Biopharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGM Biopharmaceuticals's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NGM Biopharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where NGM Biopharmaceuticals's Price-to-Owner-Earnings falls into.



NGM Biopharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

NGM Biopharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.54/-1.94
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGM Biopharmaceuticals  (NAS:NGM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


NGM Biopharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Executives
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich officer: Principal Accounting Officer C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen director, officer: Chief Scientific Officer 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse director, officer: CEO and acting CFO 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Headlines

From GuruFocus

NGM Bio to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 05-25-2023

RHO CAPITAL PARTNERS INC Cuts Portfolio Down to Size in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-04-2022

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

By Stock market mentor Stock market mentor 01-09-2023